High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis. METHODS: We conducted a double-blind, randomized, placebo-controlled multicenter study that assessed the effectiveness over one year of a high oral dose of acetylcysteine (600 mg three times daily) added to standard therapy with prednisone plus azathioprine. The primary end points were changes between baseline and month 12 in vital capacity and in single-breath carbon monoxide diffusing capacity (DL(CO)). RESULTS: A total of 182 patients were randomly assigned to treatment (92 to acetylcysteine and 90 to placebo). Of these patients, 155 (80 assigned to acetylcysteine and 75 to placebo) had usual interstitial pneumonia, as confirmed by high-resolution computed tomography and histologic findings reviewed by expert committees, and did not withdraw consent before the start of treatment. Fifty-seven of the 80 patients taking acetylcysteine (71 percent) and 51 of the 75 patients taking placebo (68 percent) completed one year of treatment. Acetylcysteine slowed the deterioration of vital capacity and DL(CO): at 12 months, the absolute differences in the change from baseline between patients taking acetylcysteine and those taking placebo were 0.18 liter (95 percent confidence interval, 0.03 to 0.32), or a relative difference of 9 percent, for vital capacity (P=0.02), and 0.75 mmol per minute per kilopascal (95 percent confidence interval, 0.27 to 1.23), or 24 percent, for DL(CO) (P=0.003). Mortality during the study was 9 percent among patients taking acetylcysteine and 11 percent among those taking placebo (P=0.69). There were no significant differences in the type or severity of adverse events between patients taking acetylcysteine and those taking placebo, except for a significantly lower rate of myelotoxic effects in the group taking acetylcysteine (P=0.03). CONCLUSIONS: Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“PANTHER-IPF, compared this three-drug combination (acetylcysteine, prednisone, and azathioprine) to acetylcysteine alone and placebo and found an increased rate of hospitalizations and death (P=0.01) in the triple therapy arm compared to placebo [62]. No physiological or clinical benefit was found in the triple therapy group”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, a recent trial with high doses of the antioxidant acetylcysteine appeared to attenuate the progression of IPF (25).”
From Adult-onset pulmonary fibrosis caused by mutations in telomerase (2007) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 1×
“Blood alkaline phosphatase increased 6 6 (8) 1 1 (1)”
BackgroundGross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 962
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Mechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808 · cited 3×
“Blood lactate dehydrogenase increased 6 6 (8) 2 2 (3)”
BackgroundChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764 · cited 1×
“Respiratory tract infection† 22 20 (25) 27 24 (32)”
Research works printed but not linked: 6
- 15. thione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994;7:431-6.
- 29. Quanjer PH. Standardized lung function testing: report of working party. Bull Eur Physiopathol Respir 1983;19:Suppl 5:195.
- 30. Standardized lung function testing: official statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:1-100.
- 12. functional trends. Am J Respir Crit Care Med 2003;168:531-7.
- 37. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH guidelines: 'efficacy' topics. E6. Good clinical practice: consolidated guideline. (Accessed October 28, 2005, at http://www. ich.org/cache/compo/276-254-1.html.)
- 23. vival in idiopathic pulmonary fibrosis. Eur Respir J 2005;25:96-103.
Cited by
Items 501–600 of 960
Alterations in the membrane-associated proteome fraction of alveolar macrophages in sarcoidosis.
Kjellin, H., Silva, E., Branca, R. M., Eklúnd, A., Jakobsson, P., Grünewald, J., Lehtiö, J., & Wheelock, Å. M. (2016) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 22
Kopincová, J., Kolomaznik, M., Mikolka, P., Košútová, P., Topercerová, J., Matasová, K., Čalkovská, A., & Mokrá, D. (2019) · Molecules · doi:10.3390/molecules24050905 · Cited by 16
Dejcman, D., Skowasch, D., Pizarro, C., Krause, A., Thomas, D., & Schäfer, V. S. (2020) · Current Rheumatology Reviews · doi:10.2174/1573397116666200905122757 · Cited by 16
Goos, T., Sadeleer, L. D., Yserbyt, J., Verleden, G. M., Vermant, M., Verleden, S. E., & Wuyts, W. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061330 · Cited by 17
“Thereafter, it was thought that an oxidant–antioxidant imbalance may contribute to this process of fibrosis in IPF, leading to the IFIGENIA-trial in 2005 [9].”
BackgroundTreatment of Idiopathic Pulmonary Fibrosis
Abuserewa, S. T. H., Duff, R., & Becker, G. (2021) · Cureus · doi:10.7759/cureus.15360 · Cited by 18
“Azathioprine-prednisone in combination with N-acetylcysteine or even N-acetylcysteine as a monotherapy has been used for many years as it was supposed to have some benefit according to the preliminary results of IFIGENIA (Idiopathic Pulmonary Fibrosis International Group Exploring (N) acetylcysteine I Annual) trial [8…”
BackgroundYou, J., Wang, J., Xie, L., Zhu, C., & Xiong, J. (2016) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2016.07.005 · Cited by 16
Role of mucolytics in the management of COPD
Poole, P. (2006) · International Journal of COPD · doi:10.2147/copd.2006.1.2.123 · Cited by 23
“There is a recent report of study involving 198 patients with pulmonary fibrosis (Demedts et al 2005) showing a small but significant preservation of lung function in the group treated with NAC 600 mg 3 times daily for 1 year in addition to usual therapy, compared with the group treated with…”
Clinical trials and tribulations--lessons from pulmonary fibrosis
Olson, A. L., Swigris, J. J., & Brown, K. K. (2012) · QJM · doi:10.1093/qjmed/hcs066 · Cited by 15
An update on current and emerging drug treatments for idiopathic pulmonary fibrosis
Trachalaki, A., Sultana, N., & Wells, A. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2213436 · Cited by 15
“Previously high dose NAC in addition to azathioprine and prednisolone was efficient in preserving Vital capacity and DLCO [129].”
BackgroundNutzenbewertung in besonderen Situationen – Seltene Erkrankungen
Windeler, J., & Lange, S. (2008) · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen · doi:10.1016/j.zgesun.2007.12.005 · Cited by 16
Síndrome por anticuerpos antisintetasa
Ruiz, A. L.-I., Araguás, E. T., & Selva-O’Callaghan, A. (2011) · Medicina Clínica · doi:10.1016/j.medcli.2011.02.026 · Cited by 15
In search of the fibrotic epithelial cell: opportunities for a collaborative network
Jenkins, G. R., Blanchard, A. D., Borok, Z., Bradding, P., Ehrhardt, C., Fisher, A. J., Hirani, N., Johnson, S. R., Königshoff, M., Maher, T. M., et al. (2011) · Thorax · doi:10.1136/thoraxjnl-2011-200195 · Cited by 16
Idiopathic pulmonary fibrosis: current challenges and future perspectives
Richeldi, L. (2013) · European Respiratory Review · doi:10.1183/09059180.00001413 · Cited by 18
Therapeutic Update in Idiopathic Pulmonary Fibrosis
Chan, A. L., Rafii, R., Louie, S., & Albertson, T. E. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8244-9 · Cited by 16
“After 12 months of treatment, the rate of decline in the FVC and DLco were significantly lower in the NAC group with a 9% relative reduction of the FVC decline and a 24% relative reduction in the DLco decline [15, 34].”
BackgroundSyndrome d'emphysème des sommets et fibrose pulmonaire des bases combinés
Cottin, V., Brillet, P., Nunès, H., & Cordier, J.-F. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2007.03.005 · Cited by 18
Martínez, J. A. B., Ferreira, J. C., Tanni, S. É., Alves, L. R., Cabral, B. F., de Carvalho, C. R. R., Cezare, T. J., da Costa, C. H., Gazzana, M. B., Jezler, S. F. D. O., et al. (2020) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20190423 · Cited by 18
“(11) Participants who received NAC plus a corticosteroid and azathioprine had a significant reduction in the rate of decline in FVC and in DLCO.(11) In contrast, studies of inhaled or oral NAC monotherapy versus placebo demonstrated no significant differences in the evolution of lung function or in other clinical outc…”
BackgroundMethodInfluentialLost in translation; from animal models of pulmonary fibrosis to human disease
Maher, T. M., & Wells, A. U. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01618.x · Cited by 17
Idiopathic pulmonary fibrosis: present understanding and future options
du Bois, R. M. (2011) · European Respiratory Review · doi:10.1183/09059180.00001511 · Cited by 16
Hasselbalch, H. C., Junker, P., Skov, V., Kjær, L., Knudsen, T. A., Larsen, M. K., Holmström, M. O., Andersen, M. H., Jensen, C., Karsdal, M. A., et al. (2023) · Cancers · doi:10.3390/cancers15174323 · Cited by 16
Lipoic Acid Suppression of Neutrophil Respiratory Burst: Effect of NADPH
O’Neill, H. C., Rancourt, R. C., & White, C. W. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1890 · Cited by 14
“NAC, in conjunction with prednisone and azathioprine, has been shown to maintain lung vital capacity and single-breath carbon monoxide diffusing capacity in IPF patients (6, 14, 16).”
Porte, J., & Jenkins, G. R. (2014) · Pharmacology Research & Perspectives · doi:10.1002/prp2.30 · Cited by 18
“Despite the considerable evidence implicating TGF-b in pulmonary fibrosis, no specific inhibitors of TGF-b have emerged as therapies for IPF.”
BackgroundInfluentialImmunosuppressive Therapy for Autoimmune Lung Diseases
Meyer, K. C., & Bierach, J. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.07.001 · Cited by 14
Recent advances in managing idiopathic pulmonary fibrosis
Scelfo, C., Caminati, A., & Harari, S. A. (2017) · F1000Research · doi:10.12688/f1000research.10720.1 · Cited by 15
New Therapeutic Avenues for Treatment of Fibrosis: Can We Learn from Other Diseases?
Rogler, G. (2014) · Digestive Diseases · doi:10.1159/000367825 · Cited by 15
Pires, F. S., Mota, P. C., Melo, N. C. V., Costa, D., Jesus, J. M., Cunha, R., Guimarães, S., Souto-Moura, C., & Morais, A. (2013) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppneu.2012.05.002 · Cited by 19
Grady, E. E., Barron, J. T., & Wagner, R. H. (2011) · Journal of Nuclear Cardiology · doi:10.1007/s12350-011-9373-0 · Cited by 14
Where do we stand with IPF treatment?
Albera, C., Ferrero, C., Rindone, E., Zanotto, S., & Rizza, E. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-s1-s7 · Cited by 14
“This is mainly due to data coming from the IFIGENIA study, [6] which despite its numerous limitations suggested preservation of lung function in patients with IPF.”
MethodBarret, M., Batteux, F., Beuvon, F., Mangialavori, L., Chryssostalis, A., Praticò, C. A., Chaussade, S., & Prat, F. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-8 · Cited by 14
A Clinicianʼs Guide to the Diagnosis and Treatment of Interstitial Lung Diseases
Danoff, S. K., Terry, P. B., & Horton, M. R. (2007) · Southern Medical Journal · doi:10.1097/smj.0b013e3180485c62 · Cited by 16
“with standard of care (prednisone and azathioprine).(35) In addition, although demonstrating promising results in a small phase II trial, interferongamma has recently been shown to be ineffective in altering disease progression or mortality in a large multinational clinical trial.”
BackgroundAn observational examination of the literature in diagnostic anatomic pathology
Foucar, E., & Wick, M. R. (2005) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2006.01.005 · Cited by 14
Zhao, L., Xiao, K., Wang, H., Wang, Z., Sun, L., Zhang, F., Zhang, X., Tang, F., & He, W. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03962.x · Cited by 15
Asian Dust Particles Induce TGF-β1via Reactive Oxygen Species in Bronchial Epithelial Cells
Kyung, S. Y., Yoon, J. Y., Kim, Y. J., Lee, S. P., Park, J.-W., & Jeong, S. H. (2012) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2012.73.2.84 · Cited by 14
Londner, C., Dandachi, G. A., Plantier, L., Juvin, K., Chevalier-Bidaud, B., Mahut, B., Israël‐Biet, D., & Delclaux, C. (2013) · Respiration · doi:10.1159/000351110 · Cited by 14
Podolanczuk, A. J., Noth, I., & Raghu, G. (2021) · European Respiratory Journal · doi:10.1183/13993003.03551-2020 · Cited by 17
Gümüştaş, S., Inan, N., Akansel, G., Başyïğït, I., & Cïftçi, E. (2013) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 28
Antisynthetase antibody syndrome: case report and review of the literature
Uribe, L., Ronderos, D. M., Díaz, M. C., Gutiérrez, J. M., Mallarino, C., & Fernández-Ávila, D. G. (2013) · Clinical Rheumatology · doi:10.1007/s10067-013-2207-5 · Cited by 13
Miyazaki, Y., Azuma, A., Inase, N., Taniguchi, H., Ogura, T., Inoue, E., Takeuchi, M., Yoshizawa, Y., Sugiyama, Y., & Kudoh, S. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.05.002 · Cited by 13
“This compared with the approximately 150–200 mL loss of FVC/year in placebo-group patients in previous studies [17–20].”
BackgroundResultInfluentialVassalou, E. E., Raissaki, M., Magkanas, E., Antoniou, K. M., & Karantanas, A. H. (2017) · Journal of Ultrasound in Medicine · doi:10.1002/jum.14406 · Cited by 13
Xiao, T., Ren, S., Bao, J., Gao, D., Sun, R., Gu, X., Gao, J., Chen, S., Jin, J., Wei, L., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175438 · Cited by 14
Avdeev, S. N. (2015) · PULMONOLOGIYA · doi:10.18093/0869-0189-2015-25-5-600-612 · Cited by 15
Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis
Nambiar, A. M., Anzueto, A., & Peters, J. I. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176312 · Cited by 13
Update in Diffuse Parenchymal Lung Disease 2008
Behr, J., & Thannickal, V. J. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200901-0011up · Cited by 15
Self-citationRandomisierte klinische Studien (RCTF)
Windeler, J., Antes, G., Behrens, J., Donner‐Banzhoff, N., & Lelgemann, M. (2008) · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen · doi:10.1016/j.zefq.2008.05.002 · Cited by 19
Libra, A., Colaci, M., Spicuzza, L., Luca, G. D., Sg, F., Pashalidis, G., Ferrara, C. A., Ielo, G., Sambataro, D., Rosa, G. L., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020369 · Cited by 14
“New revisions of IPAF criteria should take into consideration the possibility of removing the morphological domain, thus classifying UIPAF and IPAF together in the same definition.”
BackgroundEmerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?
Costabel, U. (2011) · European Respiratory Review · doi:10.1183/09059180.00002011 · Cited by 12
Self-citationPires, F. S., Mota, P. C., Melo, N. C. V., Costa, D., Jesus, J. M., Cunha, R., Guimarães, S., Souto-Moura, C., & Morais, A. (2013) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2012.06.003 · Cited by 14
Interstitial lung disease in rheumatoid arthritis: an update on diagnosis and management
Malik, S., Saravanan, V., & Kelly, C. A. (2012) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.12.24 · Cited by 13
G protein-coupled receptor 56 regulates matrix production and motility of lung fibroblasts
Yang, J., Wang, Z., Leng, D., Dai, H., Wang, J., Liang, J., Jiang, D., & Wang, C. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214529395 · Cited by 13
Ianni, A., Hofmann, M., Kumari, P., Tarighi, S., Al-tamari, H. M., Görgens, A., Giebel, B., Nolte, H., Krüger, M., Salwig, I., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.639162 · Cited by 12
“9:639162. doi: 10.3389/fcell.2021.639162 Depletion of Numb and Numblike in Murine Lung Epithelial Cells Ameliorates Bleomycin-Induced Lung Fibrosis by Inhibiting the β-Catenin Signaling Pathway Alessandro Ianni1†, Michael Hofmann1†, Poonam Kumari1, Shahriar Tarighi1, Hamza M Al-Tamari2, André Görgens3, Bernd Giebel3,…”
BackgroundInfluentialA Practical Approach to Connective Tissue Disease-Associated Lung Disease
Fischer, A., & du Bois, R. M. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9771-5_12 · Cited by 13
Okuda, R., Matsushima, H., Oba, T., Kawabe, R., Matsubayashi, M., Amano, M., Nishizawa, T., & Honda, K. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.10.001 · Cited by 15
“The IFIGENIA trial, which was published in 2005, demonstrated significant differences between a three-drug regimen (oral N-acetylcysteine 600 mg three times daily, added to a standard regimen of prednisone and azathioprine) and a standard two-drug regimen (prednisoneþazathioprine), with regard to the deterioration of…”
BackgroundMethodNew Developments in the Therapy of Pulmonary Fibrosis
Scriabine, A., & Rabin, D. U. (2009) · Advances in pharmacology · doi:10.1016/s1054-3589(08)57011-6 · Cited by 14
Assayag, D., Vittinghoff, E., Ryerson, C. J., Cocconcelli, E., Tonelli, R., Hu, X., Elicker, B. M., Golden, J. A., Jones, K. D., King, T. E., et al. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.06.012 · Cited by 14
Branley, H. M., du Bois, R. M., Wells, A. U., & Jones, H. A. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.03.005 · Cited by 12
Zimmermann, G., Reithmann, C., Strauss, T., Hatz, R., Brenner, P., Überfuhr, A., Frey, L., Nikolaou, K., & Behr, J. (2009) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.11.001 · Cited by 12
Self-citationDecreased Apoptotic Rate of Alveolar Macrophages of Patients with Idiopathic Pulmonary Fibrosis
Drakopanagiotakis, F., Xifteri, A., Tsiambas, E., Karameris, A., Tsakanika, K., Karagiannidis, N., Mermigkis, D., Polychronopoulos, V., & Bouros, D. (2012) · Pulmonary Medicine · doi:10.1155/2012/981730 · Cited by 13
“Bcl-2 density 149,8 [131, 3–170, 8] 151,7 [138, 0–166, 9] 0.”
InfluentialFibrose pulmonaire idiopathique
Cottin, V., & Cordier, J.-F. (2008) · La Presse Médicale · doi:10.1016/j.lpm.2008.01.024 · Cited by 12
Idiopathic Interstitial Pneumonias
King, T. E. (2006) · Humana Press eBooks · doi:10.1007/978-1-59259-963-9_21 · Cited by 12
Idiopathic pulmonary fibrosis trials: recommendations for the jury
Nathan, S. D., & du Bois, R. M. (2011) · European Respiratory Journal · doi:10.1183/09031936.00068611 · Cited by 12
A Small Change in FVC But a Big Change for IPF: Defining the Minimal Clinically Important Difference
Behr, J. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201110-1794ed · Cited by 13
Self-citationIdiopatic pulmonary fibrosis: A new paradigm
Avdeev, S. N. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh2017891112-122 · Cited by 13
Gillissen, A. (2011) · Pneumologie · doi:10.1055/s-0030-1256592 · Cited by 14
Management of Idiopathic Pulmonary Fibrosis
Cerri, S., Spagnolo, P., Luppi, F., & Richeldi, L. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.11.005 · Cited by 13
Novel approaches to pulmonary fibrosis
Jenkins, G. R., & Goodwin, A. T. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-6-s45 · Cited by 11
Natarajan, S., & Subramanian, P. (2015) · Turkish Thoracic Journal · doi:10.5152/ttd.2015.4584 · Cited by 11
“Treatment data: Treatment in patients diagnosed as IPF from 2008 to 2012 were given as per the ATS/ERS joint statement 2002 [2,8].”
Santoleri, F., Auriemma, L., Spacone, A., Marinari, S., Esposito, F., Vita, F. D., Petragnani, G., Fabio, C. D., Fabio, L. D., & Costantini, A. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211008625 · Cited by 14
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials
Sgalla, G., Lerede, M., & Richeldi, L. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1931119 · Cited by 13
“Following the encouraging results of the 2005 IFIGENIA study [35], NAC became routinely used in clinical practice alongside corticosteroids and immunosuppressive agents to treat IPF patients.”
ResultBiphasic effects of free radical scavengers against bleomycin-induced pulmonary fibrosis
Fujita, M., Mizuta, Y., Ikegame, S., Ouchi, H., Ye, Q., Harada, E., Inoshima, I., Yoshimi, M., Watanabe, K., & Nakanishi, Y. (2008) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2008.06.006 · Cited by 11
Troy, L. K., Chapman, S. A., Lake, F., WILSHER, M. L., Honeysett, L., Macansh, S., & Corte, T. J. (2015) · Respirology · doi:10.1111/resp.12512 · Cited by 11
Treating IPF—all or nothing? A PRO‐CON debate
Behr, J., Kolb, M. R. J., & Cox, G. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01645.x · Cited by 11
Self-citationInterstitial lung disease: trials and tribulations
Afshar, K., & Sharma, O. P. (2008) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283043e58 · Cited by 12
Stability of acetylcysteine solution repackaged in oral syringes and associated cost savings
Kiser, T. H., Oldland, A. R., & Fish, D. N. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060425 · Cited by 11
Future targets in the management of systemic sclerosis
Tyndall, A., Matucci‐Cerinic, M., & Müller‐Ladner, U. (2006) · Rheumatology · doi:10.1093/rheumatology/kep106 · Cited by 15
Idiopathic Pulmonary Fibrosis Pathogenesis and Novel Approaches to Immunomodulation
Wells, A. U., & Kelleher, W. P. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201302-0336ed · Cited by 12
Obesity, longevity, quality of life: Alteration by dietary 2-mercaptoethanol
Click, R. E. (2010) · Virulence · doi:10.4161/viru.1.6.13803 · Cited by 10
Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease
Fischer, A., Brown, K. K., & Frankel, S. K. (2009) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0b013e31819b5400 · Cited by 10
“In one large trial of IPF patients, AZA plus CS plus the antioxidant N-acetylcysteine has been shown to preserve lung function as measured by FVC and DLCO compared with CS plus AZA alone.(49) It is not known whether similar efficacy can be extrapolated for CTD-related UIP.”
BackgroundManagement of Idiopathic Pulmonary Fibrosis
Fioret, D., Roman, J., & Perez, R. L. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31821fbdbc · Cited by 12
Kumar, I., Siddiqui, Z., Verma, A., Chokhani, A., Srivastava, G. N., & Shukla, R. C. (2021) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_145_20 · Cited by 10
“[4] Current therapeutic regimens in most of the centers rely on combined usage of corticosteroid, immunosuppressive drugs, and N‐acetyl cysteine.[5] Accurate staging of disease severity and its serial monitoring thus is central to the effective management protocols of ILD.”
Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
Alhamad, E. (2015) · Annals of Thoracic Medicine · doi:10.4103/1817-1737.146866 · Cited by 10
Role of proteomics in the investigation of pulmonary fibrosis
Govender, P., Baugh, J. A., Pennington, S. R., Dunn, M. J., & Donnelly, S. C. (2007) · Expert Review of Proteomics · doi:10.1586/14789450.4.3.379 · Cited by 11
Therapeutic Management of Idiopathic Pulmonary Fibrosis: An Evidence-Based Approach
Nathan, S. D. (2006) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2005.08.004 · Cited by 10
Sandbo, N. K. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_8 · Cited by 13
Koegelenberg, C. F. N., Ainslie, G., Dheda, K. U. J., Allwood, B., Wong, M., Lalloo, U., Abdool-Gaffar, M. S., Khalfey, H., & Irusen, E. M. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.12.05 · Cited by 10
“This was in view of the 2005 IFIGENIA study which showed less decline in FVC and DLCO at 12 months when NAC was added to prednisone and azathioprine (23).”
Li, Y.-J., Shimizu, T., Shinkai, Y., Hirata, Y., Inagaki, H., Takeda, K., Azuma, A., Yamamoto, M. P., & Kawada, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030649 · Cited by 11
Diffuse parenchymal lung disease
Maher, T. M. (2008) · Medicine · doi:10.1016/j.mpmed.2008.02.003 · Cited by 10
Thabut, G., Crestani, B., Porcher, R., & Richeldi, L. (2015) · European Respiratory Journal · doi:10.1183/13993003.02204-2014 · Cited by 10
Pirfenidone should be prescribed for patients with idiopathic pulmonary fibrosis: Table 1
Jenkins, G. R. (2013) · Thorax · doi:10.1136/thoraxjnl-2011-201268 · Cited by 10
Hot off the breath: a big step forward for idiopathic pulmonary fibrosis
Ryerson, C. J., & Collard, H. R. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-205892 · Cited by 10
Etanercept for Idiopathic Pulmonary Fibrosis: Lessons on Clinical Trial Design
Jackson, R. M., & Fell, C. D. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200808-1223ed · Cited by 10
Wu, X., Li, W., Luo, Z., & Chen, Y. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02861-w · Cited by 9
“In addition, a RCT(IFIGENIA), compared NAC + therapy including Prednisone and Azathioprine with Prednisone + Azathioprine + Placebo, found that NAC group can better improve VC and DLCO in IPF patients [82].”
ResultManagement of interstitial lung disease in elderly patients
Meyer, K. C. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283541337 · Cited by 10
“the placebo and NAC cohorts [56], and the prior phase 3 IFIGENIA study that suggested benefit for NPA had not included a placebo arm and did not demonstrate an effect on survival [57].”
ResultConsensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis
Cordeiro, C. R., Campos, P., Carvalho, L., Campainha, S., Clemente, S., Figueiredo, L., Jesus, J. M., Marqués, J., Souto-Moura, C., Basto, R. P., et al. (2016) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2016.01.003 · Cited by 19
Acetylcysteine in IPF: the knockout blow?
Wijsenbeek, M. S., & Collard, H. R. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30085-6 · Cited by 9
Efficacy study of edaravone and acetylcysteine towards bleomycin-induced rat pulmonary fibrosis.
Yu, W., Tian, L., & Cheng, W. (2015) · Europe PMC (PubMed Central) · Cited by 9
Lee, S. H., Han, M. S., Lee, T., Lee, D. B., Park, J. H., Lee, S. H., & Kim, T. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1086381 · Cited by 9
The Treatment of Pulmonary Sarcoidosis
Baughman, R. P., & Drent, M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8927-6_3 · Cited by 9
Prise en charge thérapeutique de la sclérodermie systémique
Mouthon, L., BEREZNE, A., Poiraudeau, S., & Guillevin, L. (2006) · La Presse Médicale · doi:10.1016/s0755-4982(06)74932-6 · Cited by 9
High dose intracoronary N-acetylcysteine in a porcine model of ST-elevation myocardial infarction
Meyer, M., Bell, S. P., Chen, Z., Nyotowidjojo, I. S., Lachapelle, R. R., Christian, T. F., Gibson, P. C., Keating, F. K., Dauerman, H. L., & LeWinter, M. M. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0901-4 · Cited by 9
Enfermedades pulmonares intersticiales difusas
Xaubet, A., Molina‐Molina, M., & Sánchez, M. (2007) · Archivos de Bronconeumología · doi:10.1016/s0300-2896(07)71175-4 · Cited by 10
Mohammadi‐Bardbori, A., & Ghazi‐Khansari, M. (2007) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2007.06.001 · Cited by 10
Metadata
- Authors
- Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., Nicholson, A. G., Verbeken, E. K., Verschakelen, J., Flower, C. D. R., Capron, F., Petruzzelli, S., De Vuyst, P., van den Bosch, J. M. M., Rodriguez-Becerra, E., Corvasce, G., Lankhorst, I., Sardina, M., & Montanari, M.
- Affiliations
- KU Leuven (BE)
- LMU Klinikum (DE)
- Johannes Gutenberg University Mainz (DE)
- Ruhrlandklinik (DE)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Edinburgh (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Royal Brompton Hospital (GB)
- Hôpital Antoine-Béclère (FR)
- University of Pisa (IT)
- Zambon (Italy) (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-24
- Volume
- 353
- Issue
- 21
- Pages
- 2229-2242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125322938
- Cited by
- 964
- References
- 48
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 33 · 2023: 32 · 2022: 17 · 2021: 29 · 2020: 28 · 2019: 26 · 2018: 24 · 2017: 31 · 2016: 49 · 2015: 64 · 2014: 63 · 2013: 72 · 2012: 79
- FWCI
- 48.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Document Server@UHasselt (UHasselt) (submittedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- idiopathic pulmonary fibrosis, N-acetylcysteine, usual interstitial pneumonia, prednisone, azathioprine, vital capacity, diffusing capacity for carbon monoxide, lung function decline, mortality, myelosuppression, antioxidant therapy, disease-modifying therapy, treatment efficacy and safety, adverse events
- MeSH terms
- Acetylcysteine, Aged, Anti-Inflammatory Agents, Antioxidants, Azathioprine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Prednisone, Pulmonary Diffusing Capacity, Pulmonary Fibrosis, Vital Capacity, Exercise Tolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.